JP2019507174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507174A5 JP2019507174A5 JP2018546477A JP2018546477A JP2019507174A5 JP 2019507174 A5 JP2019507174 A5 JP 2019507174A5 JP 2018546477 A JP2018546477 A JP 2018546477A JP 2018546477 A JP2018546477 A JP 2018546477A JP 2019507174 A5 JP2019507174 A5 JP 2019507174A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- liraglutide
- subject
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 6
- 108010019598 Liraglutide Proteins 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 229960002701 liraglutide Drugs 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 231100001160 nonlethal Toxicity 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739 | 2016-03-04 | ||
| EP16158739.9 | 2016-03-04 | ||
| EP16173917.2 | 2016-06-10 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329.8 | 2016-06-13 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| US15/401,651 | 2017-01-09 | ||
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507174A JP2019507174A (ja) | 2019-03-14 |
| JP2019507174A5 true JP2019507174A5 (enExample) | 2020-03-26 |
| JP6940512B2 JP6940512B2 (ja) | 2021-09-29 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546477A Active JP6940512B2 (ja) | 2016-03-04 | 2017-03-03 | 心血管疾患におけるリラグルチド |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (enExample) |
| EP (1) | EP3423082B1 (enExample) |
| JP (1) | JP6940512B2 (enExample) |
| KR (1) | KR102417455B1 (enExample) |
| CN (2) | CN108778317A (enExample) |
| AU (2) | AU2017225841A1 (enExample) |
| BR (1) | BR112018067344A2 (enExample) |
| CA (1) | CA3013532C (enExample) |
| CL (1) | CL2018002515A1 (enExample) |
| DK (1) | DK3423082T5 (enExample) |
| ES (1) | ES2893755T3 (enExample) |
| HR (1) | HRP20211492T1 (enExample) |
| HU (1) | HUE055844T2 (enExample) |
| IL (1) | IL261169B (enExample) |
| MA (1) | MA43704A (enExample) |
| MX (1) | MX394179B (enExample) |
| MY (1) | MY195657A (enExample) |
| PH (1) | PH12018501844B1 (enExample) |
| PL (1) | PL3423082T3 (enExample) |
| RS (1) | RS62501B1 (enExample) |
| RU (1) | RU2745604C2 (enExample) |
| SI (1) | SI3423082T1 (enExample) |
| WO (1) | WO2017149112A1 (enExample) |
| ZA (1) | ZA201805538B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| CN118987224A (zh) * | 2020-12-16 | 2024-11-22 | 香港中文大学 | 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| JP2005535569A (ja) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１アゴニスト及び心臓血管合併症 |
| CN104826116A (zh) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| WO2009030738A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| JP2016510795A (ja) | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| JP6507154B2 (ja) | 2013-06-14 | 2019-04-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active Active
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en not_active Ceased
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh active Pending
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en active Active
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 PH PH1/2018/501844A patent/PH12018501844B1/en unknown
- 2017-03-03 MX MX2018010097A patent/MX394179B/es unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (enExample) | ||
| FI3989972T3 (fi) | Glukakonin kaltainen peptidi 1 reseptorin agonistit | |
| JP2014524480A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2018138578A5 (enExample) | ||
| JP2010222367A5 (enExample) | ||
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| JP2015038135A5 (enExample) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| JP2016539921A5 (enExample) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| Duems-Noriega et al. | Subcutaneous fluid and drug delivery: safe, efficient and inexpensive | |
| JP2019507174A5 (enExample) | ||
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| MA45625A (fr) | Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl | |
| JP2020510045A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| Roila et al. | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting | |
| JP2022035920A5 (enExample) | ||
| JP2021004249A5 (enExample) | ||
| JP2020510043A5 (enExample) |